Data availability
The histology slides and the reconstructed PET images are available upon request.
References
Zhou Y, et al. [(68) Ga]Ga-DOTA-FAPI-04 PET/CT imaging of cirrhosis with hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2023;50(5):1536–7. https://doi.org/10.1007/s00259-022-06077-0.
Desai A, Sandhu S, Lai JP, Sandhu DS. Hepatocellular carcinoma in non-cirrhotic liver: a comprehensive review. World J Hepatol. 2019;11(1):1–18. https://doi.org/10.4254/wjh.v11.i1.1.
Yen YH, Cheng YF, Wang JH, Lin CC, Wang CC. Characteristics and etiologies of hepatocellular carcinoma in patients without cirrhosis: when East meets West. PloS One. 2021;16(1):e0244939. https://doi.org/10.1371/journal.pone.0244939.
Gerin JL, Cote PJ, Korba BE, Tennant BC. Hepadnavirus-induced liver cancer in woodchucks. Cancer Detect Prev. 1989;14(2): 227–9. Available: http://www.ncbi.nlm.nih.gov/pubmed/2695243.
Aravalli RN, Steer CJ. “Animal models of liver cancer,” in Hepatocellular carcinoma: cellular and molecular mechanisms and novel therapeutic strategies. Cham: Springer International Publishing; 2014. p. 47–50.
Sergeeva O, et al. PET imaging of hepatocellular carcinoma using ZD2-((68)Ga-NOTA). J Hepatocell Carcinoma. 2023;10:291–301. https://doi.org/10.2147/JHC.S390939.
Attieh Y, et al. Cancer-associated fibroblasts lead tumor invasion through integrin-beta3-dependent fibronectin assembly. J Cell Biol. 2017;216(11):3509–20. https://doi.org/10.1083/jcb.201702033.
Erdogan B, et al. Cancer-associated fibroblasts promote directional cancer cell migration by aligning fibronectin. J Cell Biol. 2017;216(11):3799–816. https://doi.org/10.1083/jcb.201704053.
Pang Y, Wang P, Xu W, Zhao L, Chen H. Identification of isolated hepatic sarcoidosis with [(18)F]FDG and [(68) Ga]Ga-FAPI PET/CT. Eur J Nucl Med Mol Imaging. 2023. https://doi.org/10.1007/s00259-023-06236-x.
Ghoneim S, Williams SD. Hepatic sarcoidosis: an uncommon cause of cirrhosis. Cureus. 2019;11(12):e6316. https://doi.org/10.7759/cureus.6316.
Kratochwil C, et al. (68)Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60(6):801–5. https://doi.org/10.2967/jnumed.119.227967.
Acknowledgements
We thank Olga Sergeeva and Wei Cao for PET imaging along with the staff of Nuclear Medicine at University Hospitals Cleveland Medical Center, ARC staff of Case Western Reserve University for animal handling, and Maxim Sergeev for providing radiopharmaceuticals for this study.
Funding
This work is supported in part by NIH R01 grants CA204373, CA235152, and CA211762 and DoD grant W81XWH-22–1-0784.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics approval
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
Conflict of interest
Zhenghong Lee declares that he has no conflict of interest. Zheng-Rong Lu declares that he has no conflict of interest. Sandra Sexton declares that she has no conflict of interest. Wei Xin declares that he has no conflict of interest.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Lee, Z., Lu, ZR., Sexton, S. et al. PET imaging with FAPI-ligands for non-cirrhotic hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 50, 3190–3191 (2023). https://doi.org/10.1007/s00259-023-06324-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-023-06324-y